Login to Your Account

Deals And M&A NEWS

Aeterna Zentaris Inc. and Sinopharm A-think Pharmaceuticals Co. Ltd. signed an exclusive license and technology transfer agreement allowing Sinopharm A-think to develop, manufacture and commercialize Aeterna Zentaris' zoptarelin doxorubicinA in China, Hong Kong and Macau. 

DUBLIN – Geneuro SA is getting $47 million in an up-front payment and research funding and could earn $408 million more in development and commercial milestones from a deal with Les Laboratoires Servier involving its first-in-class phase II multiple sclerosis (MS) antibody GNbAC1.
Lee's Pharmaceutical, of Hong Kong, has licensed from Ikaria Inc., of Hampton, N.J., the rights for Inomax, an inhaled nitric oxide that treats hypoxic respiratory failure in newborns of 34 weeks gestational age.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: